Bionure, CataloniaBio & HealhtTech member, has launched a crowdfunding campaign through the Spanish platform of Capital Cell with the objective of raising €1.3M that will be used to finance the preparation of the Phase 2 study of its neuroprotectant BN201.
BN201 is a drug for the treatment of Acute Optic Neuritis (AON) and Multiple Sclerosis (MS), for which there are still high unmet medical needs.
The Catalan company has appointed Dr Lucia Septién-Vélez as new chief medical officer (CMO), reinforcing the team at a turning point for the company that plans to start a Phase 2 clinical study. She worked at major pharmaceutical companies, including Pfizer, Wyeth, GSK, Servier and Ipsen.
Bionure is part of the accelerator of the GAEM Foundation and is based at the Barcelona Science Park (PCB).
Presentation to interested investors
To answer the questions of the people interested in investing, Bionure organizes on May 22 the meeting Bionure - Meet the team with their CEO and CMO.
Comments